Your browser doesn't support javascript.
loading
DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study.
Kim, Stefano; Vendrely, Véronique; Saint, Angélique; André, Thierry; Vaflard, Pauline; Samalin, Emmanuelle; Pernot, Simon; Bouché, Oliver; Zubir, Mustapha; Desrame, Jérôme; de la Fouchardière, Christelle; Smith, Denis; Ghiringhelli, François; Vienot, Angélique; Jacquin, Marion; Klajer, Elodie; Nguyen, Thierry; François, Éric; Taieb, Julien; Le Malicot, Karine; Vernerey, Dewi; Meurisse, Aurélia; Borg, Christophe.
Afiliación
  • Kim S; Clinical Investigational Center, INSERM CIC-1431, Centre Hospitalier Universitaire de Besançon, Besançon, France. stefano.kim@univ-fcomte.fr.
  • Vendrely V; INSERM Unit 1098, University of Bourgogne Franche-Comté, Besançon, France. stefano.kim@univ-fcomte.fr.
  • Saint A; Department of Oncology, Sanatorio Allende, Cordoba, Argentina. stefano.kim@univ-fcomte.fr.
  • André T; Department of Radiation Oncology, Bordeaux University Hospital, Pessac, France.
  • Vaflard P; Department of Oncology, Centre Antoine Lacassagne, Nice, France.
  • Samalin E; Sorbonne Université and Hôpital Saint Antoine, Paris, France.
  • Pernot S; Department of Oncology, Institut Curie, Paris, France.
  • Bouché O; Department of Oncology, Institut du Cancer de Montpellier, Montpellier, France.
  • Zubir M; Department of Oncology, Institut Bergonié, Bordeaux, France.
  • Desrame J; Department of Digestive Oncology, Université de Reims Champagne Ardenne, CHU Reims, Reims, France.
  • de la Fouchardière C; Department of Oncology, Hôpital Privé des Peupliers, Paris, France.
  • Smith D; Department of Oncology, Hôpital Privé Jean Mermoz, Lyon, France.
  • Ghiringhelli F; Department of Oncology, Centre Léon Bérard, Lyon, France.
  • Vienot A; Department of Oncology, Bordeaux University Hospital, Bordeaux, France.
  • Jacquin M; Department of Oncology, Centre Georges-François Leclerc, Dijon, France.
  • Klajer E; Clinical Investigational Center, INSERM CIC-1431, Centre Hospitalier Universitaire de Besançon, Besançon, France.
  • Nguyen T; INSERM Unit 1098, University of Bourgogne Franche-Comté, Besançon, France.
  • François É; Department of Oncology, University Hospital of Besançon, Besançon, France.
  • Taieb J; Clinical Investigational Center, INSERM CIC-1431, Centre Hospitalier Universitaire de Besançon, Besançon, France.
  • Le Malicot K; Cancéropôle Grand-Est, Strasbourg, France.
  • Vernerey D; Department of Oncology, University Hospital of Besançon, Besançon, France.
  • Meurisse A; Department of Oncology, University Hospital of Besançon, Besançon, France.
  • Borg C; Hôpital Nord Franche Comté, Montbéliard, France.
Exp Hematol Oncol ; 12(1): 63, 2023 Jul 21.
Article en En | MEDLINE | ID: mdl-37480095
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline Idioma: En Revista: Exp Hematol Oncol Año: 2023 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline Idioma: En Revista: Exp Hematol Oncol Año: 2023 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido